Lynparza recommended for approval in the EU by CHMP for BRCA-mutated metastatic castration-resistant prostate cancer
21 September 2020 07:05 BST Lynparza recommended for approval in the EU by CHMP forBRCA-mutated metastatic castration-resistant prostate cancer Only PARP inhibitor to improve overall survival vs. newhormonal agent treatments in advanced prostate cancer AstraZeneca and MSD's Lynparza (olaparib) has been recommended for marketing authorisation in the European Union (EU) for patients with metastatic castration-resistant prostate cancer (mCRPC) with breast cancer susceptibility gene 1/2 (BRCA1/2) mutations, a subpopulation of homologous recombination repair (HRR) gene mutations.